Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL174397 | 0.92 | FFAR3 (0.32) | CYP2C19FFAR3 | |
| Hydrochloric Acid SCHEMBL4359360 | 0.90 | FFAR3 (0.31) | FFAR3 | |
| Hydrochloric Acid SCHEMBL2198959 | 0.90 | FFAR3 (0.31) | FFAR3 | |
| SCHEMBL741463 | 0.79 | — | — | |
| SCHEMBL2489958 | 0.78 | FFAR3 (0.36) | FFAR3 | |
| SCHEMBL31711959 | 0.78 | ITGB1 (0.40) | — | |
| SCHEMBL7387847 | 0.74 | NPSR1 (0.37) | — | |
| SCHEMBL20599744 | 0.74 | CYP3A4 (0.32) | — | |
| SCHEMBL7713581 | 0.73 | CYP2C19 (0.32) | CYP2C19AKR1C1 | |
| SCHEMBL29025934 | 0.73 | DGAT1 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7344704-B2 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | SCHERING AG (DE) | 2008-03-18 | — | — | US | claimed |
| EP-1088558-B1 | Galenic formulations comprising paramagnetic and diamagnetic compounds | BAYER SCHERING PHARMA AG (DE) | 2007-06-27 | — | — | EP | claimed |
| EP-1519756-B1 | USE OF METAL COMPLEXES CONTAINING PERFLUOROALKYL AS CONTRAST AGENTS IN MAGNETIC RESONANCE IMAGING FOR REPRESENTING INTRAVASCULAR THROMBI | BAYER SCHERING PHARMA AG (DE) | 2007-05-02 | — | — | EP | claimed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | claimed |
| US-20040131546-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | SCHERING AG (DE) | 2004-07-08 | — | — | US | claimed |
| US-20030095924-A1 | Galenical formulations | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-22 | — | — | US | claimed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | claimed |
| WO-2025041528-A1 | OILY SOLID COSMETIC AND HARDNESS IMPROVER FOR OILY SOLID COSMETIC | 日清オイリオグループ株式会社 | 2025-02-27 | — | — | WO | disclosed |
| WO-2023163035-A1 | OLIGOESTER AND COSMETIC CONTAINING SAID OLIGOESTER | 日清オイリオグループ株式会社 | 2023-08-31 | — | — | WO | disclosed |
| CN-105517574-B | The combination product of hepatitis C virus inhibitors | 百时美施贵宝公司 | 2019-01-18 | — | — | CN | disclosed |
| US-20070269384-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of Alzheimer's disease | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-11-22 | — | — | US | disclosed |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| US-6818203-B2 | COMPLEXES HAVE CRITICAL MICELLE FORMATION CONCENTRATION, HYDRODYNAMIC MICELLE DIAMETER, AND PROTON RELAXIVITY IN PLASMA CONTRAST MEDIA IN MR IMAGING | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-11-16 | — | — | US | disclosed |
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2003-04-17 | — | — | US | disclosed |
| EP-0219936-A1 | Novel platinum complexes | Nippon Kayaku Kabushiki Kaisha (JP) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030072713-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, PTDSS1 | CYP2C19 4551/4885AKR1C1 3420/4885FFAR3 16/4885 |
| US-20050074409-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses | FABP3, PRF1, MALT1 | CYP2C19 4192/4885AKR1C1 2675/4885FFAR3 8/4885 |
| US-20040131546-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of intravascular thrombi | PF4, FGB, F2 | CYP2C19 3708/4885AKR1C1 2719/4885FFAR3 23/4885 |
| US-20030095924-A1 | Galenical formulations | GALR1, GALR2, LGALS1 | CYP2C19 1173/4885AKR1C1 1370/4885FFAR3 9/4885 |
| US-20070269384-A1 | Use of perfluoroalkyl-containing metal complexes as contrast media for diagnosis of Alzheimer's disease | APP, APBA1, PSEN1 | CYP2C19 3784/4885AKR1C1 2315/4885FFAR3 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.